AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32819962 — intervention group
Group type: COMPARATOR
Intervention: Control group (no corticosteroids)
Number of subjects: 0
Study 33446078 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory-vocal task combined with a visual-manual task during seven practice sessions
Number of subjects: 0
Study 35126620 — intervention group
Group type: EXPERIMENTAL
Intervention: Shuangshen Decoction combined with immunological preparations
Number of subjects: 90
Study 35126620 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment and immune agents (routine group)
Number of subjects: 90
Study 33155422 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronally Advanced Lingual Flap (CALF)
Number of subjects: 40
Study 33155422 — intervention group
Group type: COMPARATOR
Intervention: Periosteal Releasing Incision (PRI)
Number of subjects: 40
Study 33155422 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Periosteal Releasing Incision (MPRI)
Number of subjects: 40
Study 33155422 — intervention group
Group type: EXPERIMENTAL
Intervention: Double Flap Incision (DF)
Number of subjects: 40
Study 35900116 — intervention group
Group type: EXPERIMENTAL
Intervention: eHealth Mindful Movement and Breathing (eMMB)
Number of subjects: 31
Study 35900116 — intervention group
Group type: COMPARATOR
Intervention: Empathic attention control (AC)
Number of subjects: 31
Study 33626166 — intervention group
Group type: EXPERIMENTAL
Intervention: Prompt treatment (≤ 6 days)
Number of subjects: 625
Study 33626166 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed treatment (> 10 days)
Number of subjects: 625
Study 32383449 — intervention group
Group type: EXPERIMENTAL
Intervention: Active mHealth follow-up (trimonthly phone calls to update vital status)
Number of subjects: 1490
Study 32383449 — intervention group
Group type: EXPERIMENTAL
Intervention: Active mHealth follow-up
Number of subjects: 1490
Study 34091120 — intervention group
Group type: EXPERIMENTAL
Intervention: Acquired antithrombin deficiency (AT<80%) at 72 hours post-admission
Number of subjects: 579
Study 34091120 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients who developed VTE
Number of subjects: 579
Study 33331917 — intervention group
Group type: EXPERIMENTAL
Intervention: Low plasma Aβ42/40 (≤0.107)
Number of subjects: 483
Study 33331917 — intervention group
Group type: COMPARATOR
Intervention: Plasma Aβ42/40 ratio > 0.107
Number of subjects: 483
Study 35882054 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutral trigger warning
Number of subjects: 123
Study 35882054 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive trigger warning
Number of subjects: 123
Study 35882054 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative trigger warning
Number of subjects: 123
Study 35882054 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher PTSD scores
Number of subjects: 123
Study 32947581 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based College (MB-College)
Number of subjects: 96
Study 32947581 — intervention group
Group type: COMPARATOR
Intervention: Enhanced usual care control
Number of subjects: 96
Study 33017509 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal Er:YAG LASER application
Number of subjects: 24
Study 33017509 — intervention group
Group type: COMPARATOR
Intervention: Sham manipulation
Number of subjects: 24
Study 33017509 — intervention group
Group type: COMPARATOR
Intervention: Oestrogen replacement
Number of subjects: 24
Study 33646447 — intervention group
Group type: EXPERIMENTAL
Intervention: Autoimmune rheumatic diseases (ARD)
Number of subjects: 103117
Study 33646447 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymyositis and dermatomyositis (PM/DM)
Number of subjects: 103117
Study 33646447 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic sclerosis (SSc)
Number of subjects: 103117
Study 33646447 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic lupus erythematosus (SLE)
Number of subjects: 103117
Study 33646447 — intervention group
Group type: EXPERIMENTAL
Intervention: Sjogren’s syndrome (SjS)
Number of subjects: 103117
Study 33646447 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily oral steroid dose of >10 mg
Number of subjects: 103117
Study 33646447 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate
Number of subjects: 103117
Study 33646447 — intervention group
Group type: EXPERIMENTAL
Intervention: Other immunosuppressants (injected steroids, cyclophosphamide, biological agents, methotrexate, cyclosporine)
Number of subjects: 103117
Study 33646447 — intervention group
Group type: EXPERIMENTAL
Intervention: Comorbidities (male sex, cancer, HIV, interstitial lung disease)
Number of subjects: 103117
Study 32159882 — intervention group
Group type: EXPERIMENTAL
Intervention: Dacomitinib 45 mg once daily
Number of subjects: 81
Study 32159882 — intervention group
Group type: COMPARATOR
Intervention: Gefitinib 250 mg once daily
Number of subjects: 81
Study 32159882 — intervention group
Group type: EXPERIMENTAL
Intervention: Dacomitinib
Number of subjects: 81
Study 32159882 — intervention group
Group type: COMPARATOR
Intervention: Gefitinib
Number of subjects: 81
Study 34735310 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined Training (CT)
Number of subjects: 2
Study 34735310 — intervention group
Group type: COMPARATOR
Intervention: Multicomponent Training (MT)
Number of subjects: 2
Study 33626088 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotionally arousing segments identified based on HRV synchrony
Number of subjects: 21
Study 33626088 — intervention group
Group type: COMPARATOR
Intervention: Randomly selected segments as control
Number of subjects: 21
Study 32720384 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose omega-3 icosapent ethyl
Number of subjects: 3789
Study 32720384 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3789
Study 35443264 — intervention group
Group type: EXPERIMENTAL
Intervention: Open sky access osteotomy using a 2‐mm curved osteotome
Number of subjects: 40
Study 35443264 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous perforating method
Number of subjects: 40
Study 32016876 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid ANN-WOA model
Number of subjects: 217
Study 32016876 — intervention group
Group type: COMPARATOR
Intervention: Core optimization models of ANN and MLR
Number of subjects: 217
Study 98327681 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg oral tolcapone
Number of subjects: 24
Study 98327681 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg intravenous tolcapone
Number of subjects: 24
Study 98327681 — intervention group
Group type: EXPERIMENTAL
Intervention: Half of the recommended dosage of tolcapone
Number of subjects: 24
Study 98327681 — intervention group
Group type: COMPARATOR
Intervention: Moderate chronic hepatitis
Number of subjects: 24
Study 33527488 — intervention group
Group type: EXPERIMENTAL
Intervention: High intensity exercise
Number of subjects: 577
Study 33527488 — intervention group
Group type: COMPARATOR
Intervention: Low-to-moderate intensity exercise
Number of subjects: 577
Study 33527488 — intervention group
Group type: EXPERIMENTAL
Intervention: High intensity exercise with behavior change support (BCS)
Number of subjects: 577
Study 33527488 — intervention group
Group type: COMPARATOR
Intervention: Low-to-moderate intensity exercise with behavior change support (BCS)
Number of subjects: 577
Study 36284318 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran (110 or 150 mg twice daily)
Number of subjects: 200
Study 36284318 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 200
Study 33693475 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-dimensional cell culture, spheroids, organoids, microfluidic devices, organ-on-a-chip systems, living animal and human cardiac tissues
Number of subjects: 0
Study 33693475 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive designs, master protocols, drug repurposing, in silico trials, N-of-1 trials
Number of subjects: 0
Study 32860005 — intervention group
Group type: EXPERIMENTAL
Intervention: Forsythin (single oral administration)
Number of subjects: 0
Study 32488889 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-based dental health education (DHE)
Number of subjects: 60
Study 32488889 — intervention group
Group type: COMPARATOR
Intervention: Conventional dental health education (DHE)
Number of subjects: 60
Study 34436562 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher educational attainment (4.2 years of schooling)
Number of subjects: 14384
Study 34436562 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher educational attainment
Number of subjects: 14384
Study 34436562 — intervention group
Group type: COMPARATOR
Intervention: Smoking exposure
Number of subjects: 14384
Study 34436562 — intervention group
Group type: COMPARATOR
Intervention: BMI
Number of subjects: 14384
Study 34436562 — intervention group
Group type: COMPARATOR
Intervention: Smoking and BMI combined
Number of subjects: 14384
Study 33896622 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 60
Study 33896622 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Number of subjects: 60
Study 34253047 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran
Number of subjects: 7396
Study 34253047 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 7396
Study 34253047 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 7396
Study 34253047 — intervention group
Group type: COMPARATOR
Intervention: Vitamin K antagonists
Number of subjects: 7396
Study 32612194 — intervention group
Group type: EXPERIMENTAL
Intervention: Sub-maximal running exercise (30 min at 80% heart rate reserve)
Number of subjects: 20
Study 32612194 — intervention group
Group type: COMPARATOR
Intervention: Resting control
Number of subjects: 20
Study 34936232 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac sodium
Number of subjects: 100
Study 34936232 — intervention group
Group type: COMPARATOR
Intervention: Hydrocodone/acetaminophen (APAP)
Number of subjects: 100
Study 33342630 — intervention group
Group type: COMPARATOR
Intervention: Mitomycin C (MMC)
Number of subjects: 26
Study 33342630 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyvinylpyrrolidone Collagen (PVP)
Number of subjects: 26
Study 34842189 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral type 1 IFN
Number of subjects: 0
Study 34842189 — intervention group
Group type: COMPARATOR
Intervention: Best medical therapy
Number of subjects: 0
Study 32427014 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication information (Med info)
Number of subjects: 114
Study 32427014 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral information (Beh info)
Number of subjects: 114
Study 32427014 — intervention group
Group type: COMPARATOR
Intervention: No change (control group)
Number of subjects: 114
Study 32427014 — intervention group
Group type: COMPARATOR
Intervention: Reverse video (Rev Vid; also no change)
Number of subjects: 114
Study 34851533 — intervention group
Group type: EXPERIMENTAL
Intervention: EM100 (eccentric phase velocity of 100%)
Number of subjects: 40
Study 34851533 — intervention group
Group type: EXPERIMENTAL
Intervention: EM150 (eccentric phase velocity of 150%)
Number of subjects: 40
Study 34851533 — intervention group
Group type: EXPERIMENTAL
Intervention: FW (conventional flywheel device)
Number of subjects: 40
Study 34851533 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study 36256646 — intervention group
Group type: EXPERIMENTAL
Intervention: IB160 + 15μg H7N9
Number of subjects: 432
Study 36256646 — intervention group
Group type: EXPERIMENTAL
Intervention: IB160 + 7.5μg H7N9
Number of subjects: 432
Study 36256646 — intervention group
Group type: EXPERIMENTAL
Intervention: IB160 + 3.75μg H7N9
Number of subjects: 432
Study 36256646 — intervention group
Group type: EXPERIMENTAL
Intervention: SE + 15μg H7N9
Number of subjects: 432
Study 36256646 — intervention group
Group type: EXPERIMENTAL
Intervention: SE + 7.5μg H7N9
Number of subjects: 432
Study 36256646 — intervention group
Group type: EXPERIMENTAL
Intervention: SE + 3.75μg H7N9
Number of subjects: 432
Study 36256646 — intervention group
Group type: EXPERIMENTAL
Intervention: unadjuvanted vaccine 15μg H7N9
Number of subjects: 432
Study 36256646 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 432
Study 34609452 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous scopolamine butylbromide, 20 mg four times a day (n=79)
Number of subjects: 162
Study 34609452 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=78)
Number of subjects: 162
Study 34609452 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous scopolamine butylbromide
Number of subjects: 162
Study 34609452 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 162
Study 35852024 — intervention group
Group type: EXPERIMENTAL
Intervention: Smaller bottles (37.5-cl)
Number of subjects: 260
Study 35852024 — intervention group
Group type: EXPERIMENTAL
Intervention: Smaller glasses (290 ml)
Number of subjects: 260
Study 35852024 — intervention group
Group type: COMPARATOR
Intervention: Larger bottles (75-cl)
Number of subjects: 260
Study 35852024 — intervention group
Group type: COMPARATOR
Intervention: Larger glasses (370 ml)
Number of subjects: 260
Study 33346183 — intervention group
Group type: EXPERIMENTAL
Intervention: Piezosurgery
Number of subjects: 100
Study 33346183 — intervention group
Group type: COMPARATOR
Intervention: Saw techniques
Number of subjects: 100
Study 34251396 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent intervention including seminars, online courses, management algorithms, communication tips, and feedback reports on antimicrobial prescribing.
Number of subjects: 426
Study 34251396 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent intervention
Number of subjects: 426
Study 34251396 — intervention group
Group type: COMPARATOR
Intervention: Control group (routine care)
Number of subjects: 426
Study 32125875 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic Intraligamentary Stabilization (DIS)
Number of subjects: 85
Study 32125875 — intervention group
Group type: COMPARATOR
Intervention: Primary ACL Reconstruction (ACLR)
Number of subjects: 85
Study 36302662 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous alteplase
Number of subjects: 490
Study 36302662 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 490
Study 34391263 — intervention group
Group type: EXPERIMENTAL
Intervention: Finding-oriented manual therapy techniques (MTT), 9 treatments over a three-week period
Number of subjects: 9
Study 34391263 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 9
Study 32078510 — intervention group
Group type: EXPERIMENTAL
Intervention: Six Eye Exercises protocol (experimental group)
Number of subjects: 20
Study 32078510 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care protocol (control group)
Number of subjects: 20
Study 35945582 — intervention group
Group type: EXPERIMENTAL
Intervention: Online self-help intervention based on Acceptance and Commitment Therapy (ACT) for 8 weeks with therapeutic email guidance
Number of subjects: 146
Study 35945582 — intervention group
Group type: COMPARATOR
Intervention: Waiting list condition (WLC)
Number of subjects: 146
Study 34698557 — intervention group
Group type: EXPERIMENTAL
Intervention: Theaflavins (TFs) for 6 weeks
Number of subjects: 56
Study 34698557 — intervention group
Group type: EXPERIMENTAL
Intervention: Theaflavins (TFs)
Number of subjects: 56
Study 34698557 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 32345348 — intervention group
Group type: EXPERIMENTAL
Intervention: Intense regimen of 12-h IO-therapy per day for 4 weeks
Number of subjects: 56
Study 32345348 — intervention group
Group type: COMPARATOR
Intervention: Standard regimen of 4-h IO-therapy per day for 12 weeks
Number of subjects: 56
Study 32345348 — intervention group
Group type: EXPERIMENTAL
Intervention: Intense regimen of IO-therapy
Number of subjects: 56
Study 32345348 — intervention group
Group type: COMPARATOR
Intervention: Standard regimen of IO-therapy
Number of subjects: 56
Study 32345348 — intervention group
Group type: EXPERIMENTAL
Intervention: IO-therapy
Number of subjects: 56
Study 35524938 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine buccal film (BBF) 900 µg
Number of subjects: 19
Study 35524938 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone 60 mg
Number of subjects: 19
Study 35524938 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone 30 mg
Number of subjects: 19
Study 35524938 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 34587383 — intervention group
Group type: EXPERIMENTAL
Intervention: REGEN-COV 2400-mg
Number of subjects: 2696
Study 34587383 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2696
Study 34587383 — intervention group
Group type: EXPERIMENTAL
Intervention: REGEN-COV 1200-mg
Number of subjects: 2696
Study 34587383 — intervention group
Group type: EXPERIMENTAL
Intervention: REGEN-COV 2400-mg and 1200-mg
Number of subjects: 2696
Study 34819266 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab + chemotherapy (platinum-based, ≤4 cycles) prior to surgery, followed by durvalumab monotherapy (q4w, for an additional 12 cycles post surgery)
Number of subjects: 800
Study 34819266 — intervention group
Group type: COMPARATOR
Intervention: Placebo + chemotherapy (platinum-based, ≤4 cycles) prior to surgery, followed by placebo monotherapy (q4w, for an additional 12 cycles post surgery)
Number of subjects: 800
Study 34819266 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab + chemotherapy
Number of subjects: 800
Study 34819266 — intervention group
Group type: COMPARATOR
Intervention: Placebo + chemotherapy
Number of subjects: 800
Study 35757638 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-week internet-based self-help intervention for COVID-19 related psychological distress
Number of subjects: 107
Study 34703057 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1mg/kg dexamethasone (Group A)
Number of subjects: 100
Study 34703057 — intervention group
Group type: EXPERIMENTAL
Intervention: 1μg/kg dexmedetomidine (Group B)
Number of subjects: 100
Study 33189633 — intervention group
Group type: EXPERIMENTAL
Intervention: sacubitril/valsartan
Number of subjects: 4796
Study 33189633 — intervention group
Group type: COMPARATOR
Intervention: valsartan
Number of subjects: 4796
Study 32471469 — intervention group
Group type: EXPERIMENTAL
Intervention: myPlan Kenya app
Number of subjects: 0
Study 32471469 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 0
Study 33278836 — intervention group
Group type: EXPERIMENTAL
Intervention: Orthodontic aligners (n 19)
Number of subjects: 38
Study 33278836 — intervention group
Group type: COMPARATOR
Intervention: Fixed appliance (n 19)
Number of subjects: 38
Study 32181747 — intervention group
Group type: EXPERIMENTAL
Intervention: Storytelling 4 Empowerment (S4E)
Number of subjects: 50
Study 32181747 — intervention group
Group type: COMPARATOR
Intervention: Enhanced usual practice
Number of subjects: 50
Study 36206385 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 U aboBoNT‐A solution
Number of subjects: 374
Study 36206385 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 374
Study 33530511 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcifediol weekly oral dose
Number of subjects: 107
Study 33530511 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly cholecalciferol
Number of subjects: 107
Study 33530511 — intervention group
Group type: COMPARATOR
Intervention: Monthly cholecalciferol
Number of subjects: 107
Study 33530511 — intervention group
Group type: COMPARATOR
Intervention: Single-dose cholecalciferol
Number of subjects: 107
Study 32522090 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision Regret Scale (DRS)
Number of subjects: 296
Study 34715071 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib (300 mg twice daily)
Number of subjects: 391
Study 34715071 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 391
Study 34715071 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib
Number of subjects: 391
Study 32301579 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive bias modification for interpretations (CBM-I)
Number of subjects: 24
Study 32301579 — intervention group
Group type: COMPARATOR
Intervention: Interpretation control condition (ICC)
Number of subjects: 24
Study 35917774 — intervention group
Group type: EXPERIMENTAL
Intervention: Variable-rate infusion of norepinephrine
Number of subjects: 161
Study 35917774 — intervention group
Group type: COMPARATOR
Intervention: Fixed-rate infusion of norepinephrine
Number of subjects: 161
Study 32565595 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g hydroalcoholic extract of Fenugreek seeds daily for 3 months
Number of subjects: 30
Study 32565595 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 36334705 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced intervention group (group-based DPP with weekly telephone support)
Number of subjects: 0
Study 36334705 — intervention group
Group type: COMPARATOR
Intervention: Active control group
Number of subjects: 0
Study 32043417 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate (LDX) - dose-optimised (30–70 mg/day) or fixed-dose (70 mg/day)
Number of subjects: 0
Study 32043417 — intervention group
Group type: COMPARATOR
Intervention: Osmotic-release oral system methylphenidate (OROS-MPH) or atomoxetine (ATX)
Number of subjects: 0
Study 33894078 — intervention group
Group type: EXPERIMENTAL
Intervention: Health activation measured using the Patient Activation Measure
Number of subjects: 61
Study 33894078 — intervention group
Group type: EXPERIMENTAL
Intervention: Challenges accessing care
Number of subjects: 61
Study 33894078 — intervention group
Group type: EXPERIMENTAL
Intervention: Health activation related to self-care
Number of subjects: 61
Study 33894078 — intervention group
Group type: EXPERIMENTAL
Intervention: Unique challenges in PSH
Number of subjects: 61
Study 33630646 — intervention group
Group type: EXPERIMENTAL
Intervention: CDP-Choline 500 mg
Number of subjects: 0
Study 33630646 — intervention group
Group type: EXPERIMENTAL
Intervention: CDP-Choline 1000 mg
Number of subjects: 0
Study 33630646 — intervention group
Group type: EXPERIMENTAL
Intervention: CDP-Choline 2000 mg
Number of subjects: 0
Study 33630646 — intervention group
Group type: EXPERIMENTAL
Intervention: CDP-Choline
Number of subjects: 0
Study 33630646 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 32000790 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-assisted training
Number of subjects: 40